Onkologie. 2017:11(1):8-10 | DOI: 10.36290/xon.2017.002

Renaissance of immunotherapy in treating kidney cancer

Tomáš Büchler
Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

Renal cell carcinoma (RCC) has traditionally been considered an immunogenic malignancy. Despite this, the majority of existing

immunotherapeutic strategies have brought only little benefit to patients with a generalized tumour. In some clinical settings,

however, a novel generation of immunotherapeutic drugs, particularly those from the group of checkpoint inhibitors, has shown

superiority over standard targeted therapy, while having relatively low toxicity.

Keywords: renal cell carcinoma, immunotherapy, nivolumab, biological therapy

Published: February 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Büchler T. Renaissance of immunotherapy in treating kidney cancer. Onkologie. 2017;11(1):8-10. doi: 10.36290/xon.2017.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17: 2521-2529. Go to original source... Go to PubMed...
    2. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825-830. Go to original source... Go to PubMed...
    3. Rini BI, Stenzl A, Zdrojowy R, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2016; 17: 1599-1511. Go to original source... Go to PubMed...
    4. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1803-1813. Go to original source... Go to PubMed...
    5. Plimack ER, Motzer RJ, Escudier B, et al. Two-year Efficacy and Safety Update: Phase III CheckMate 025 Study of Nivolumab vs. Everolimus in Patients With Advanced Renal Cell Carcinoma (aRCC). 2016 NCRI Cancer Conference. http://abstracts.ncri.org.uk/abstract/two-year-efficacy-and-safety-update-phase-iii-checkmate-025-study-of-nivolumab-vs-everolimus-in-patients-with-advanced-renal-cell-carcinoma-arcc//
    6. Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17: 994-1003. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.